Cover Image
Market Research Report

Biosimulation Technology

Published by Global Industry Analysts, Inc. Product code 341978
Published Content info 164 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimulation Technology
Published: September 1, 2015 Content info: 164 Pages
Description

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.
Biovia
Certara L.P
Chemical Computing Group
Entelos, Inc.

Table of Contents
Product Code: MCP-7920

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biosimulation: Massively Benefiting Drug R&D
  • Current and Future Analysis
  • Application and End-user Areas
    • Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)
    • Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)
  • Biosimulation Offers Paradigm Shift in Drug Development
  • Key Market Drivers in a Nutshell
  • Market Restraints
  • Competition

2. GROWTH DRIVERS

  • Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development
    • Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
    • Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
    • Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)
    • Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Aging Global Population Drives Advanced Drug R&D
    • Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • High Costs Associated with Traditional Drug Discovery
    • Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
    • Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)
  • High Failure Rate of Late-Stage Drug Trials
  • List of Recent Late-stage Drug Failures (2014)
  • China and India: Hot Spots for R&D Investment
    • Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)
  • Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS - AN INSIGHT

  • Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets
    • Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)
  • Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
  • Marking New Avenues in Diabetes Research
  • Biosimulation Moving From Discovery Aid to Clinical Tool
  • Lung Biosimulation: Game Changer for OIP Development
  • Biosimulation for Drug Repositioning
  • Grid-based Docking Aids Biosimulation
  • Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

  • Biosimulation - A Brief Introduction
  • Drug Discovery and Development
  • Stages in Drug Development Process
    • Target identification
    • Target Validation
    • Lead Identification
    • Lead Optimization
    • Pre-Clinical Testing
    • Clinical Trials
  • Drug Discovery Technologies
  • Human Physiology
  • Mathematical Models and Biosimulation Technique
  • Bottom-up Modeling
  • Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

  • Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0
  • Optimata Granted US Patent for Biosimulation Technology
  • Cognigen Releases Version 1.3 of KIWI™
  • Simulations Plus Releases Version 9.0 of GastroPlus™
  • Certara Launches Version 2.0 of Cardiac Safety Simulator
  • Certara Releases Version 14 of Simcyp™ Simulator
  • Certara Receives FDA Grant for MechDermA
  • Physiomics Launches EasyAP™
  • Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
  • Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

  • Certara Merges Its Pharsight Consulting with Quantitative Solutions
  • Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
  • Physiomics Signs Contract with Merck Serono
  • PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions
  • CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
  • Dassault Systemes Acquires Accelrys
  • Rhenovia Pharma Secures Series B Funding
  • Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
  • Arsenal Capital Partners Acquires Certara
  • Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Advanced Chemistry Development, Inc. (Canada)
  • Biovia (Formerly Accelrys) (US)
  • Certara L.P. (US)
  • Chemical Computing Group (Canada)
  • Entelos, Inc. (US)
  • In Silico Biosciences, Inc. (US)
  • InhibOx (UK)
  • Insilico Biotechnology AG (Germany)
  • LeadInvent Technologies (India)
  • Leadscope, Inc. (US)
  • Nimbus Therapeutics (US)
  • OpenEye Scientific Software Inc. (US)
  • Physiomics Plc. (UK)
  • Rhenovia Pharma SAS (France)
  • Schrodinger, LLC (US)
  • Simulations Plus, Inc.(US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Biosimulation to Abate Life Sciences R&D Spending
    • Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)
    • Ageing Population - Booster for Effective Drug Development
    • Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Rise in Chronic Disorders Drive Market Growth
    • Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)
    • Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)
    • Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Increasing Incidence of Cancer: A Major Growth Driver
    • Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Demand for Advanced Drug Development
    • Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Regulatory Authorities Stress on Paradigm Shift in Drug Development
    • Ageing Population Boosts Demand
    • Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Rhenovia Pharma SAS - A Key Player
  • B. Market Analytics
    • Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Insilico Biotechnology AG - A Key Player
  • B. Market Analytics
    • Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Growing Population and Aging Demographic Drive Demand for Advanced Drug Development
    • Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
    • Leadinvent Technologies (India) - A Key Player
  • B. Market Analytics
    • Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top